| DB ID | MyCo_1562 |
| Title | Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response |
| Year | 2014 |
| PMID | 24687510 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | All procedures in the study were approved by Weill Cornell Medical College’s Institutional Animal Care and Use Committee. |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Animal |
| Host Common name | Rabbit |
| Host Scientific name | Oryctolagus cuniculus |
| Biomarker Name | ANXA1 |
| Biomarker Full Name | Annexin A1 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | A well-described persistently neutropenic rabbit model of IPA was used for the experiments. The three experimental arms consisted of uninfected control animals (n 13), animals infected endotracheally with A. fumigatus and untreated (n 17), and infected rabbits treated intravenously with one of the following antifungal agents (n 16): liposomal amphotericin B (LAMB) at 5 mg/kg of body weight, deoxycholate amphotericin B (DAMB) at 1 mg/kg, or ravuconazole (RVZ) at 5 mg/kg. Neutropenia was deliberately chosen for comparison of host biomarkers’ responses during the antifungal therapy to simulate a prominent condition for human infection. |
| Cohort No. | 46 |
| Age Group | None |
| P Value | p<0.0001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) caused by Aspergillus fumigates is a devastating disease for immunocompromised patients. Successful management of patients depends on early diagnosis, effective therapy, and monitoring of therapeutic response. Detecting IPA and monitoring the response to therapy still remain very difficult, especially in the early stages of the disease. Currently, according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG), diagnosis of IPA relies on a positive computed tomography (CT) scan, culture and/or microscopic evidence of disease, and detection of A. fumigates antigens in a susceptible host. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Human haptoglobin (Hp) ELISA kit (GenWay), rabbit C-reactive protein (CRP) ELISA kit (Immunology Consultant Laboratory, Inc.), rabbit annexin A1 (Anx A1) ELISA kit (Uscn Life Science Inc.). |
| Assay Data | None |
| Validation Techniques used | ELISA, 2D gel electrophoresis, Western blotting |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
